Text
An Update, 10.12.14Malaysian Genomics Resource Centre Berhad
Our Journey So Far
2010, listing 2012-13, screening R&D 2014, screening rollout 2015, brighter future begins
© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.
Journey
Transformation
Reinvested in R&D to create new consumer segment - Screening Services Main stream of revenue from Contract Analytics Added additional streams of income: ‣ Screening Services ‣ Pathology Lab (JV with
Qualitas)
Growth
Focus on marketing. Established credentials and reputation. Tap into global industry: ‣ Outsource Contract
Analytics. ‣ More Contract Analytics
projects. Consumer focus: ‣ Pathology Lab. ‣ Screening Services, 40%
growth since 2013.
Malaysian Genomics Today
© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.
Proprietary Analytical Pipelines
Genetic & Genomic Expertise
Analytical Services
Plant Science
Human Health
Local, foreign institutions
Screening Services Pathology Lab Diagnostic Services
Local, foreign hospitals, clinics, doctors, and allied health specialists
Broadening Earnings Base
© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.
100%
Listing FY2010
100%
Analytical Services
15%5%
80%
Transformation FY2014
Analytical ServicesPathology LabScreening Services
5%20%
8%67%
Direction FY2017
Analytical ServicesPathology LabScreening ServicesDiagnostic Services
Growth Opportunities: Analytical Services
© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.
Global Market 1,2CAGR 21% (today – 2018), revenue US$8 – 12 billion 2018 est. Increase in outsourcing to Asia from US and EU.
1 BCC Research (2014). DNA Sequencing: Emerging Technologies and Applications. 2 Markets and Markets (2013). Bioinformatics Market By Sector, Segment & Application – Global Forecasts to 2017.
Key Drivers
means
more accessible sequencing
greater demand for sequencing and analysis
greater demand for sequencing and analysis
means
higher revenues for analysis due to limited supply
mean
more accessible sequencing
falling sequencing
costs
For Malaysian Genomics:We increased Analytical Services in healthcare (e.g. FELDA Wellness Project)
and in agriculture.
We started marketing beyond Malaysia for regional work.
We have seen positive transitions from Sales Pipeline to Order Book.
We are working to double the size of our Sales Pipeline before FY2016.
Growth Opportunities: Analytical Services
© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.
6.711.0
June 2014
25.0
12.0
December 2014
2.1 2.5
June 2013
Order Book (RM’m)
Sales Pipe. (RM’m)
Current Situationa) Clinipath;
has 11 branch labs serving 2,000 doctors; and operates in 7 medical centres.
b) Clinipath holds 6% share of Malaysia’s RM428 million private sector pathology market (2014 est.)
Growth Opportunities: Pathology Lab
© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.
Expansion PlanIncrease market share by; a) Increasing revenues per medical centre; b) Increasing from 7 to 10 medical centres over next 3
years; and c) Selling higher margin molecular tests.
6%
94%
2014 RM428m (est.)
10%
90%
2019 RM754m (est.)target
Current Situationa) Used for 70% of healthcare decisions made by doctors. b) Global market revenue US$80 billion (2020 est., Forbes). c) Fastest growing segment is molecular diagnostics.
Growth Opportunities: Diagnostic Services
© Copyright 2014. Malaysian Genomics Resource Centre Berhad. Private & Confidential.
Expansion Plana) Partner program with leading US and EU labs to bring best-
of-breed diagnostic tests to Malaysia. b) Looking beyond clinics to hospitals. c) Looking beyond Malaysia to region.
Text
Thank youMalaysian Genomics Resource Centre Berhad